Pharmacokinetics of Pegylated Liposomal DoxorubicinAlberto Gabizón(Shaare Zedek Medical Center), Hilary Shmeeda(Shaare Zedek Medical Center), Yechezkel BarenholzClinical PharmacokineticsJanuary 1, 200310.2165/00003088-200342050-00002Cited by 1,613SaveCiteExport RISWatch citationsAbstractRelated PapersProlonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.Alberto Gabizón, Raphael Catane, Beatrice Uziely et al.|PubMed|1994|1.4kLiposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.Beatrice Uziely, Susan Jeffers, Rut Isacson et al.|Journal of Clinical Oncology|1995|477Polyethylenglykol-umhülltes (pegyliertes) liposomales DoxorubicinAlberto Gabizón, Francisco J. Plaza Martín|Drugs|1997|477Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial.Malcolm Ranson, J Carmichael, Kenneth J. O’Byrne et al.|Journal of Clinical Oncology|1997|294Liposomes: Preparation, Characterization, and PreservationDov Lichtenberg, Yechezkel Barenholz|Methods of biochemical analysis|1988|290